Healthcare / Medical DevicesKOSDAQ
$29950.00
-1050.00 (-3.23%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 26% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-7.4B · quality 71.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
15/100
F
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
8/100
SEC 0%
Sin guardar todavía.
Market Cap
$227.8B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-27.9%
↓Gross Margin
47.7%
↓Debt/Equity
0.11
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2024–2025 · 1 años de histórico normalizado
Revenue CAGR
+34.9%
FCF CAGR
—
FCF margin
-132.2%
FCF / Net income
1.23x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $7.30B · net income $-7.86B · FCF $-9.66B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 |
|---|---|---|---|
| Income Statement | |||
| Revenue | $7.30B | $7.30B | $5.41B |
| Net Income | $-7.86B | $-7.86B | $-4.82B |
| EBITDA | $-6.64B | $-6.64B | $-2.21B |
| EPS | -1203.00 | -1203.00 | -1337.00 |
| Gross Margin | 47.7% | 47.7% | 40.9% |
| Operating Margin | -103.1% | -103.1% | -114.5% |
| Net Margin | -107.7% | -107.7% | -89.0% |
| Balance Sheet | |||
| Debt/Equity | 0.11 | 0.11 | 0.47 |
| Current Ratio | 8.13 | 8.13 | — |
| Cash Flow | |||
| Free Cash Flow | $-9.66B | $-9.66B | $-5.24B |
| Returns | |||
| ROE | -27.9% | -27.9% | -49.6% |
| Valuation | |||
| P/B | 6.94 | 6.94 | — |
| Growth & Yield | |||
| Revenue Growth | 34.9% | 34.9% | — |
| EPS Growth | 10.0% | 10.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-64.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-1337.00 → -1203.00
Residual
-64.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.